Anteris Technologies Global Corp. (ASX:AVR)
Australia
· Delayed Price · Currency is AUD | Market Cap | 202.67M |
| Revenue (ttm) | 4.37M |
| Net Income (ttm) | -123.28M |
| Shares Out | 36.06M |
| EPS (ttm) | -6.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,415 |
| Average Volume | 46,594 |
| Open | 6.58 |
| Previous Close | 5.62 |
| Day's Range | 6.58 - 7.85 |
| 52-Week Range | 4.26 - 23.45 |
| Beta | 0.47 |
| RSI | 42.00 |
| Earnings Date | Apr 28, 2025 |
About ASX:AVR
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for s... [Read more]
Financial Performance
In 2024, ASX:AVR's revenue was $2.70 million, a decrease of -1.17% compared to the previous year's $2.74 million. Losses were -$76.29 million, 65.8% more than in 2023.
Financial numbers in USD Financial StatementsNews
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris ® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed...
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year
Anteris Technologies Global Corp. reports FY results
Anteris Reports 2024 Financial Results and Provides Corporate Update
EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed ...
Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast
Tuesday, Medtronic Plc (NYSE: MDT) reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion . The medical device maker reported adjusted EPS of $1.39, beating the co...
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Barclays analyst initiates Positive coverage on ... Full story available on Benzinga.com
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC” or “Anteris”) is pleased to announce the closing of its initial public offering of 14,800,000 shares of i...
U.S. IPO Weekly Recap: ServiceTitan Shines In 3 IPO Week
Three IPOs and three SPACs listed this week - ServiceTitan, Anteris Technologies, NetClass, Mountain Lake Acquisition, Roman DBDR Acquisition II, and Jackson Acquisition II, respectively.
Anteris Technologies prices IPO at $6 per share
Anteris Technologies Global (AVR) priced IPO at $6.00 per share, trading on Nasdaq under ticker symbol AVR with proceeds for heart valve development.
Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced the pricing of its initial public offering of 14,800,000 shares of its common stock (“Co...
Anteris Technologies (AVR) Plans $100 Million IPO on Nasdaq
Anteris Technologies (AVR) Plans $100 Million IPO on Nasdaq
Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced that it has launched the roadshow for its proposed initial public offering of 14,800,000...
Anteris Technologies Targets $75 Million US IPO
Anteris Technologies Global Corp. Files Registration Statement for Proposed US Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced that it has filed a Registration Statement on Form S-1 with the U.S. Securities and Exch...
Cardiac device maker Anteris Technologies files for $75M IPO
Australian cardiac device maker Anteris Technologies Global (AVR) has filed to raise $75M through a U.S. initial public offering. Read more here.
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip™ Passes Animal Study
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of TAVR and the world's only balloon-expandable...
DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case
BRISBANE, Australia & MINNEAPOLIS--(BUSINESS WIRE)--Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR, OTC: ANTTY) reported today that DurAVR™ THV, a new class of biomimetic heart valve and ...
Anteris Technologies Commences American Depository Receipt Program
BRISBANE, Australia & MINNEAPOLIS--(BUSINESS WIRE)--Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR, OTC: ANTTY) reported today that it has established a sponsored Level 1 American Deposi...
Anteris Technologies Commences US Early Feasibility Study
BRISBANE, Australia & MINNEAPOLIS--(BUSINESS WIRE)--Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR, OTC: ANTTY) reported today that DurAVR™ Transcatheter Heart Valve (THV), a new class o...